Communiqués Cellectar Biosciences, Inc.

Actions

CLRB

US15117F8804

Produits pharmaceutiques

Temps réel estimé Cboe BZX 17:10:25 20/08/2026			Varia. 5j.	Varia. 1 janv.
2,540 ^USD	-3,05%		+1,61%	-14,58%

18/08	Transcript : Cellectar Biosciences, Inc. - Special Call
13/08	Transcript : Cellectar Biosciences, Inc., Q2 2026 Earnings Call, Aug 13, 2026

Communiqués

13/08	Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates	AQ
30/07	Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026	AQ
27/07	Translogistics Inc. Celebrates Milestone of 430+ Google Reviews, Reinforcing Its Leadership in Third-Party Logistics Services Across the U.S.	AQ
15/07	Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers	AQ
01/06	Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting	AQ
14/05	Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates	AQ
11/05	Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026	AQ
05/05	Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia	AQ
05/05	Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million	AQ
21/04	Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026	AQ
14/04	Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)	AQ
04/03	Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates	AQ
25/02	Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026	AQ
17/02	Cellectar Biosciences Expands Global Intellectual Property Estate	AQ
12/01	Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference	AQ
09/01	Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference	AQ
16/12	Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies	AQ
13/11	Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update	AQ
06/11	Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025	AQ
27/10/25	Cellectar Biosciences : Corporate Presentation - October 2025	PU
27/10/25	Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma	AQ
14/10/25	Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research	AQ
07/10/25	Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million	AQ
06/10/25	Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)	AQ
30/09/25	Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer	AQ